Trial Profile
A study of HSRx431 for the treatment of Zika virus
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Sep 2016
At a glance
- Drugs HSRx 431 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions
- 23 Sep 2016 New trial record
- 06 Sep 2016 According to a HSRx Biopharmaceutical media release, this trial anticipated in the early 2017.
Most Recent Events
Trial Overview
Purpose
This phase I study will investigate the safety of HSRx431 for the treatment of Zika virus
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| Zika virus infection | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
- Age Group adult
Patient Inclusion Criteria
patients infected with Zika virus
Trial Details
Organisations
- Affiliations HSRx Biopharmaceutical
Trial Dates
-
Initiation Dates
Planned : 01 Aug 2017
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| HSRx 431Primary Drug |
-
|
-
|
HSRx431
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 23 Sep 2016 | New trial record | New trial record Updated 23 Sep 2016 |
| 06 Sep 2016 | Other trial event | According to a HSRx Biopharmaceutical media release, this trial anticipated in the early 2017. Updated 24 Sep 2016 |
References
-
HSRx Biopharmaceutical. Broad-Spectrum Antiviral Drug HSRx 431(Tm) Tests Effective Against Zika Virus. Media-Rel 2016;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG